SIRPA and glioblastoma: Xuyao Zhang et al. revealed that a fusion protein VEGFR1D2-SIRPαD1 could effectively elicit potent anti-tumor effects for glioblastoma through disrupting angiogenetic axis and CD47-SIRPα anti-phagocytic axis (Zhang et al., 2018).